RxDoctor Payments Data

Lyndon Cagampan, MD

Physical Medicine & Rehabilitation · Dover, DENPI 1003842436

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $693 and has fallen 97.1% since, to $20 in 2025.

$2,358in general payments, 2019–2025

Across 176 payments — averaging $13.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$560
  • Biohaven Pharmaceuticals, Inc.$490
  • Biohaven Pharmaceutical Holding Company Ltd.$334
  • Scilex Pharmaceuticals Inc.$332
  • Pfizer$246
  • Collegium Pharmaceutical, Inc.$168
  • plus $228 from 5 others

What the payments were for

  • Food & beverage$2,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,358 in reported general payments places this provider in the 80th percentile of 32 physical medicine & rehabilitation providers in Delaware.

See all physical medicine & rehabilitation providers in Delaware

Medicare billing

Part B allowed, 2024
$141,154
Medicare patients
214
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl57$51,476
Xtampza ErOxycodone Myristate81$44,207
ZtlidoLidocaine21$14,971
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen474$13,289
BelbucaBuprenorphine Hcl15$12,850
Oxycodone Hcl577$9,868
Morphine Sulfate ErMorphine Sulfate208$8,532
Zolmitriptan11$5,909
Fentanyl45$4,354
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$3,518
Lidocaine24$3,208
Gabapentin165$2,897
Tramadol Hcl ErTramadol Hcl26$2,560
Buprenorphine17$2,469
Pregabalin127$2,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$168$57,05796 claims
Scilex Pharmaceuticals Inc.Ztlido$332$14,97121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 32 physical medicine & rehabilitation providers in Delaware.

Other physical medicine & rehabilitation in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →